The pleiotropic effects of YY1 in various cancers may also be due to a rewiring of the enhancer–promoter regulatory landscape, as novel enhancer-associated YY1 binding has been implicated in the progression and metastasis of hepatocellular carcinoma 76,77. Here, YY1 is linked to cancer.